GlassScriptPhysician profile
Kimberly Bates
NPI 1003392283
$6,324.82
in general payments reported to CMS, 2019-2025
31 companies · $4,493 in 2025
The $4,493 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.09 · 2023: $17.43 · 2024: $1,800 · 2025: $4,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,742 · Travel and Lodging: $1,408 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,742.47 |
| Travel and Lodging | $1,408.27 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,568.94 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $583.45 | 2024-2025 | Ultomiris |
| Sk Life Science, INC. | $564.50 | 2024-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $481.71 | 2024-2025 | Nuplazid |
| Abbvie INC. | $436.85 | 2024-2025 | |
| Emd Serono, INC. | $425.39 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $354.36 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $258.77 | 2024-2025 | Austedo Xr, Ajovy |
| Ucb, INC. | $182.88 | 2025 | Rystiggo, Briviact, Nayzilam |
| Genentech USA, INC. | $181.24 | 2024-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Axsome Therapeutics, INC. | $171.75 | 2025 | Symbravo |
| Lilly USA, LLC | $146.63 | 2024-2025 | Kisunla, Amyvid, Reyvow |
| Csl Behring | $121.28 | 2024-2025 | Hizentra |
| Vanda Pharmaceuticals INC. | $105.68 | 2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $97.72 | 2025 | Hyqvia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $89.82 | 2024 | Nourianz |
| Pfizer INC. | $77.66 | 2024-2025 | |
| Lundbeck LLC | $70.81 | 2024-2025 | Vyepti |
| Biogen, INC. | $55.54 | 2024-2025 | Vumerity, Tysabri |
| Merz Pharmaceuticals, LLC | $53.82 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Neurelis, INC. | $53.75 | 2024-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $44.39 | 2025 | Rexulti |
| Genzyme Corporation | $37.21 | 2025 | |
| Eisai INC. | $34.20 | 2025 | |
| Celgene Corporation | $33.36 | 2025 | Zeposia |
| Aucta Pharmaceuticals, INC. | $18.19 | 2025 | Motpoly Xr |
| Boston Scientific Corporation | $17.43 | 2023 | |
| Amgen INC. | $15.11 | 2024 | Aimovig |
| Astrazeneca Pharmaceuticals LP | $15.10 | 2025 | Wainua |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.09 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $13.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.